
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results
Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit of KRW 312.8 billion. FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit of KRW 983.6 billion. Strong growth momentum expected to continue …